Opaleye Management Inc. Cyma Bay Therapeutics, Inc. Transaction History

Opaleye Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $4.23 Million - $6.21 Million	566,700 New	566,700 $6.21 Million
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $371,498 - $529,069	-115,015 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$3.47 - $4.42 $399,102 - $508,366	115,015 New	115,015 $420,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $186,200 - $830,200	-140,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $716,800 - $1.01 Million	140,000 New	140,000 $717,000
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $3.33 Million - $7.51 Million	-550,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $1.43 Million - $2.35 Million	-175,000 Reduced 24.14%	550,000 $7.3 Million
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $175,926 - $315,806	26,900 Added 3.85%	725,000 $5.71 Million
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $6,528 - $8,712	600 Added 0.09%	698,100 $7.74 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $346,450 - $467,350	32,500 Added 4.89%	697,500 $9.36 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $3.96 Million - $5.49 Million	665,000	665,000 $5.36 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.